AEterna Zentaris, Nippon Kayaku sign agreement for Ozarelix in Japan

By Elaine Rigoli

Tampa, Fla., Aug. 3 - AEterna Zentaris, Inc. has entered into a licensing and collaboration agreement with Nippon Kayaku for its fourth-generation luteinizing hormone-releasing hormone antagonist, ozarelix.

Under the agreement, AEterna Zentaris granted Nippon Kayaku an exclusive license to develop and market ozarelix for all potential oncological indications in Japan.

In return, AEterna Zentaris is to receive an upfront payment upon signature and is eligible to receive payments upon achievement of certain development and regulatory milestones, in addition to low double-digit royalties on potential net sales.

Further financial details were not disclosed.

Nippon Kayaku is a pharmaceutical, agricultural and chemical company with headquarters in Tokyo.

AEterna Zentaris is a global biopharmaceutical company based in Quebec.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.